Racecadotril NEW

‌Racecadotril (CAS 81110-73-8)‌
Google Keywords: Racecadotril CAS 81110-73-8, Antidiarrheal API Manufacturing, Pediatric Diarrhea Treatment, Enkephalinase Inhibitor, GMP Gastrointestinal Drug Synthesis

🌟 ‌Product Overview‌

‌Racecadotril‌ (CAS 81110-73-8) is a potent ‌enkephalinase inhibitor‌ used to treat ‌acute diarrhea‌ by reducing intestinal fluid secretion without affecting motility. As a high-purity pharmaceutical intermediate, it is essential for synthesizing antidiarrheal drugs with rapid action and minimal side effects, particularly in pediatric and adult populations.

• ‌Primary Function‌: Blocks enkephalin degradation to prolong antidiarrheal activity and restore electrolyte balance.

• ‌Applications‌: Pediatric diarrhea management, OTC antidiarrheal formulations, and combination therapies for gastrointestinal disorders.

✅ ‌Key Advantages‌

🔹 ‌High Bioavailability‌ | >85% oral absorption | Ensures rapid onset (within 1 hour) for acute symptom relief.
🔹 ‌Pediatric Safety‌ | Clinically proven safe for children ≥3 months, with minimal adverse effects vs. traditional antidiarrheals.
🔹 ‌GMP Compliance‌ | Manufactured under ISO 9001:2015 and ICH Q7 standards, supporting FDA/EMA regulatory filings.
🔹 ‌Stability‌ | Shelf-stable under controlled conditions (2-year validity with proper storage).

🧪 ‌Applications‌

1. ‌Pediatric Medicines‌: Core ingredient in oral suspensions and granules for childhood acute diarrhea.

2. ‌Adult Antidiarrheals‌: Formulated in tablets or capsules for travelers’ diarrhea and gastroenteritis.

3. ‌Veterinary Use‌: Adopted in livestock treatments to manage diarrheal outbreaks.

4. ‌Clinical Research‌: Studied for inflammatory bowel disease (IBD) adjunct therapy.

📜 ‌Quality Assurance‌

• ‌Testing Methods‌: HPLC, GC, NMR, and mass spectrometry for purity verification and impurity profiling.

• ‌Standards‌: Complies with USP <1086>, EP 10.0, and ICH stability guidelines for pharmaceutical intermediates.

📈 ‌Market Trends‌

The ‌global antidiarrheal drugs market‌ is projected to reach ‌$8.5 billion by 2030‌ (CAGR 4.5%), driven by rising diarrheal disease prevalence, increasing pediatric healthcare investments, and demand for non-antibiotic therapies. Racecadotril’s safety profile positions it as a preferred choice in OTC and prescription markets, especially in Asia-Pacific and Africa.

Accelerate your gastrointestinal drug production with Racecadotril – precision-engineered for efficacy, safety, and regulatory compliance.